Catalyst
Slingshot members are tracking this event:
SAGE-547 nearing top-line data release date following completion of Phase 2 study, which tested 547 for efficacy in treating postpartum depression (PPD).
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SAGE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 12, 2016
Occurred Source:
http://files.shareholder.com/downloads/AMDA-2RFZJS/2378497885x0x899292/9B03718C-A6EA-49D4-BB9E-0350AC39105B/SAGE_PPD_Results_Conf_Call_FINAL.pdf
Related Projects
- Digesting the significance of SAGE-547's success in its Phase 2 postpartum depression study SAGE Executed On: Jul 29, 2016 at 12:45 PM EDT
Related Keywords
Postpartum Depresion, Hamilton Depression Rating Scale (hamd)
